Abstract
Background Obesity is linked to low-grade peripheral inflammation and is recognized as an independent risk factor for severe COVID-19. Obesity and overweight have furthermore been shown to relate to structural brain alterations. Post-COVID condition (PCC) has in turn been associated with structural brain alterations and lingering immunological changes. Therefore, in this study, we aimed to assess whether obesity contributes to structural brain alterations and differences in immunological markers in PCC patients.
Methods We investigated a previously established cohort of PCC patients (n = 61). Whole-brain comparison of gray matter volume (GMV) was conducted by voxel-based morphometry (VBM). Obesity, as measured by body mass index (BMI), as well as age, gender and total intracranial volume (TIV) were included as regressors in a linear regression model.
Results A significant negative association was found between higher BMI and lower GMV in the right thalamus (p(FWE) = 0.039, k = 209, TFCE = 1037.97, x = 18, y = −21, z = 8). Moreover, BMI, GMV and immunological markers were linked in PCC. Specifically, BMI was primarily positively associated with Interleukin-6 and negatively with Interleukin-7, while GMV showed strong positive associations with Interleukin-8.
Limitations A small cohort size and no available data on BMI changes before and after SARS-CoV2 infection limit the interpretation of our findings.
Conclusion The results suggest that BMI contributes to GMV alterations in PCC patients, with both BMI and GMV being associated with peripheral immunological markers. These findings indicate that converging mechanisms, such as inflammation and structural brain alterations, may play a role in obesity and PCC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SET was funded by the Leistungszentrum Innovative Therapeutics (TheraNova) funded by the Fraunhofer Society and the Hessian Ministry of Science and Art, the Bundesministerium fuer Bildung und Forschung (BMBF, Federal Ministry of Education)- 01EO2102 INITIALISE Advanced Clinician Scientist Program and the REISS foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The local Ethics Committee of the Medical Faculty of the University of Jena gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
